Cargando…
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
This report assesses the observed risk of PML in patients treated with the anti-CD20 monoclonal antibody rituximab in the regulatory authority-approved autoimmune indications rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). This was a cumulative...
Autores principales: | Berger, Joseph R., Malik, Vineeta, Lacey, Stuart, Brunetta, Paul, Lehane, Patricia B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992248/ https://www.ncbi.nlm.nih.gov/pubmed/29508305 http://dx.doi.org/10.1007/s13365-018-0615-7 |
Ejemplares similares
-
Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy
por: Punch, Chandra, et al.
Publicado: (2016) -
Progressive Multifocal Leukoencephalopathy
por: Adang, Laura, et al.
Publicado: (2015) -
Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab
por: Guduru, Mounika, et al.
Publicado: (2020) -
Progressive multifocal leukoencephalopathy after fingolimod treatment
por: Berger, Joseph R., et al.
Publicado: (2018) -
Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab
por: Rosenkranz, Sina C., et al.
Publicado: (2021)